ERBB2 and breast carcinoma: On the other hand, the exceptional nodal responses to neoadjuvant chemotherapy and dual Her2 blockage in Her2-positive breast cancer patients opens the way to the question of whether we can omit axillary surgery in such a group of patients or at least in a certain subgroup.